A Phase II Clinical Study of AC-201 Tablets in Subjects With Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL

Enrollment

145

Participants

Timeline

Start Date

April 23, 2024

Primary Completion Date

March 7, 2025

Study Completion Date

April 28, 2025

Conditions

Plaque Psoriasis

Interventions

DRUG

AC-201

AC-201 tablets will be administered orally

DRUG

Placebo

Matching placebo tablets will be administered orally.

Trial Locations (1)

The First Hospital of China Medical University, Shenyang

All Listed Sponsors

lead

Accro Bioscience (Suzhou) Limited

INDUSTRY

NCT06972888 - A Phase II Clinical Study of AC-201 Tablets in Subjects With Plaque Psoriasis | Biotech Hunter | Biotech Hunter